Kangfang Biological (9926jackpotpartycasinopokies.HK) plunged nearly 45% to HK$26.45 in intraday trading, its share price hit a new low since October 2022, and its turnover so far has enlarged to over HK$1.1 billion. It is reported that the Chinese Phase III clinical data of Kangfang Biotech AK112 and EGFR-TKi treated non-small cell lung cancer fell short of expectations.

Also worth notingjackpotpartycasinopokiesYes, the summary of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was officially released today. The TROP2-targeted antibody-conjugated drug (ADC)sacituzumab tirumotecan(SKB264/MK-2870), jointly developed by Merck (MSD) and Kelun-Biotech, has demonstrated outstanding results in a phase 3 trial in the treatment of advanced triple negative breast cancer (TNBC). Analysis showed that progression-free survival (PFS) of patients with high TROP2 expression who received SKB264 alone was more than three times that of patients in the chemotherapy group.